Search Results for "emtricitabine"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for emtricitabine. Results 21 to 22 of 22 total matches.

Juluca - A Two-Drug Complete Regimen for HIV (online only)

   
The Medical Letter on Drugs and Therapeutics • Dec 03, 2018  (Issue 1561)
-1 infection most often includes 2 NRTIs (abacavir/ lamivudine or tenofovir/emtricitabine ...
The FDA has approved Juluca (ViiV Healthcare/Janssen), a fixed-dose combination of the integrase strand transfer inhibitor (INSTI) dolutegravir (Tivicay) and the non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine (Edurant), as a once-daily complete regimen for treatment of adults with HIV-1 infection who do not have a history of treatment failure or known substitutions associated with resistance to either drug and have been taking a stable suppressive antiretroviral regimen for ≥6 months. Dolutegravir/rilpivirine is the first complete regimen to be approved for...
Med Lett Drugs Ther. 2018 Dec 3;60(1561):e202-4 |  Show IntroductionHide Introduction

Tenofovir Alafenamide (Vemlidy) for Hepatitis B

   
The Medical Letter on Drugs and Therapeutics • Jan 02, 2017  (Issue 1511)
Hepsera (Gilead) 1238.20 Emtricitabine – Emtriva (Gilead) 200 mg caps; 10 mg/mL oral soln 200 mg PO once ...
The FDA has approved tenofovir alafenamide (Vemlidy – Gilead) for treatment of chronic hepatitis B virus (HBV) infection in adults with compensated liver disease. It is the first single-drug product containing tenofovir alafenamide (TAF), a prodrug of the nucleotide reverse transcriptase inhibitor tenofovir, to become available; several combination products containing TAF are approved for treatment of HIV-1 infection. Tenofovir disoproxil fumarate (TDF; Viread – Gilead), another tenofovir prodrug, has been used for many years for treatment of chronic HBV infection; a generic...
Med Lett Drugs Ther. 2017 Jan 2;59(1511):6-8 |  Show IntroductionHide Introduction